TABLE 2.
Baseline characteristics in 60 neonates and infants
| Characteristicsa | No. of patients | Mean (SD) | Median (range) |
|---|---|---|---|
| Total patients | 60 | ||
| Gender (male/female) | 39/21 | ||
| Race (Caucasian/Asian/unknown) | 53/5/2 | ||
| IUGR | 3 | ||
| GA (wks) | 30.4 (5.8) | 27.9 (23.3–42.0) | |
| PMA (wks) | 35.7 (6.5) | 36.5 (24.9–47.9) | |
| PNA (days) | 38 (30) | 27 (5–121) | |
| Birth wt (g) | 1,518 (884) | 1,115 (540–3850) | |
| Current wt (g) | 2,060 (1020) | 1,955 (700–4200) | |
| Serum creatinine concn (μmol/liter) | 52 (32) | 41 (22–164) | |
| Ciprofloxacin treatment | |||
| Duration (days) | 5 (4) | 5 (1–17) | |
| Dose (mg/dose) | 18.9 (10.1) | 18.7 (4.5–40.0) | |
| Dose (mg/kg/dose) | 9.1 (1.6) | 9.7 (4.4–11.0) | |
| Comedication | |||
| Inotropic agents | 22 | ||
| Teicoplanin | 41 | ||
| Diuretics | 30 | ||
| Caffeine | 15 | ||
| Amoxicillin-clavulanic acid | 12 | ||
| Nystatin | 12 | ||
| Colistin-tobramycin-amphotericin B | 10 |
a
IUGR, intrauterine growth restriction; GA, gestational age at birth; PMA, postmenstrual age; PNA, postnatal age.